One-Year Pharmacovigilance Update of Brodalumab

M Lebwohl; C Leonardi; JJ Wu; P Yamauchi; N Rawnsley; M Merchant; A Jacobson

M Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY;

C Leonardi

Saint Louis University School of Medicine, St Louis, MO

JJ Wu

Dermatology Research and Education Foundation, Irvine, CA

P Yamauchi

Dermatology Institute & Skin Care Center, Santa Monica, CA

N Rawnsley

Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ

M Merchant

Bausch Health US, LLC, Bridgewater, NJ

A Jacobson

Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ

Keywords

Brodalumab, Psoriasis

Abstract

Abstract not available.

References

1. Siliq [package insert]. Bridgewater, NJ: Bausch Health US, LLC; 2017.
2. Lebwohl et al. N Engl J Med. 2015;373:1318-1328. 3. Papp et al. Br J Dermatol. 2016;175:273-286.

Poster PDF

Published

Jan 28, 2020

How to Cite

Lebwohl, M., Leonardi, C., Wu, J., Yamauchi, P., Rawnsley, N., Merchant, M., & Jacobson, A. (2020). One-Year Pharmacovigilance Update of Brodalumab. SKIN The Journal of Cutaneous Medicine, 4(1), S24. Retrieved from https://jofskin.org/33014/index.php/skin/article/view/814

Issue

Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

Section

Dermatopharmacology

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

KA Papp, M Lebwohl, AB Gottlieb, M Sebastian, R Langley, Y Okubo, M Wang, C Cioffi, F Staelens, K Reich, Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich, Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
K Reich, A Blauvelt, M Lebwohl, KA Papp, P Rich, B Strober, D De Cuyper, C Madden, L Peterson, V Vanvoorden, RB Warren, Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
M Lebwohl, M Siegel, L Shankle, L Pisenti, M Yassine, S Van Vorhees, A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich, Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
D Tha?i, A Blauvelt, K Reich, RB Warren, V Piguet, F Brock, F Fierens, V Ciaravino, M Lebwohl, Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
C Leonardi, K Fahrbach, B Neupane, A Armstrong , K Gordon, S Kiri, V Taieb, L McClung, Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
A.B. Gottlieb, D Thaci, C Leonardi, Y Poulin, S Kavanagh, M Boehnlein, K Reich, Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
A Blauvelt, C Paul, P van de Kerkhof, R B Warren, A B Gottlieb, R G Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich, Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)

1 2 3 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)